"An oral combination treatment may prevent the progression of advanced leiomyosarcoma, one of the most common subtypes of soft tissue sarcoma, according to a recent study published in The Lancet Oncology. "These findings support the combination as a potential treatment option for patients with advanced leiomyosarcoma and provide a strong rationale for further study aimed at improving outcomes in this difficult-to-treat cancer," the Seth Pollack, MD, the Steven T. Rosen, MD, Professor of Cancer Biology and a co-author of the study."
"In the current study, the investigators aimed to determine whether a combination treatment of cabozantinib, a tyrosine kinase inhibitor, and the oral chemotherapy drug temozolomide could slow disease progression in patients with advanced leiomyosarcoma. Cabozantinib inhibits pathways involved in tumor growth and blood vessel formation specifically by blocking the VEGF receptor, which is overexpressed in sarcoma tumor cells. Temozolomide, which is part of the standard of care for sarcoma treatment, can be administered over long periods of time."
Leiomyosarcoma is a rare cancer arising from uncontrolled growth of smooth muscle cells that can rapidly metastasize to organs containing smooth muscle, including the digestive tract, blood vessels, and uterus. Standard systemic therapies for advanced disease include doxorubicin, gemcitabine-based regimens, trabectedin, and pazopanib, but average survival remains about two years. An oral therapeutic combination of cabozantinib, a tyrosine kinase inhibitor targeting VEGF-driven angiogenesis, and temozolomide, an oral alkylating chemotherapy, demonstrated the ability to slow disease progression in patients with advanced leiomyosarcoma, supporting further clinical evaluation to improve outcomes.
Read at News Center
Unable to calculate read time
Collection
[
|
...
]